Pharmaceutical Products for CDER Research Studies - IDIQ

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

FDA OFFICE OF ACQ GRANT SVCS

Contract Value

Not provided

Codes & Classification
Solicitation Number

75F40126Q132721

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

UNITED STATES

SourceSAM
Documents3
The Food and Drug Administration (FDA), operating under the Department of Health and Human Services, has issued a combined synopsis/solicitation for an Indefinite Delivery/Indefinite Quantity (IDIQ) contract titled "Pharmaceutical Products for CDER Research Studies." This procurement is managed by the FDA Office of Acquisition and Grant Services and is intended to support the Center for Drug Evaluation and Research (CDER) in its ongoing research initiatives. The primary purpose of this contract is to secure pharmaceutical products necessary for CDER research studies, ensuring the FDA has reliable access to high-quality pharmaceutical preparations to advance its scientific and regulatory mission. The scope encompasses the manufacturing and supply of pharmaceutical products, as classified under NAICS Code 325412 (Pharmaceutical Preparation Manufacturing), with the corresponding Product Service Code 6505. The place of performance is within the United States. The procurement is structured as an IDIQ contract, allowing for flexible ordering of products as research needs arise over the contract period. The previous contract for similar requirements was held by WE Pharma, LLC, under contract number 75F40120D00032, with a ceiling value of $9,500,000.00 and a period of performance from September 30, 2020, to September 29, 2025. While historical pricing and awarded pricing structures are not disclosed in this solicitation, interested parties may request such information through the Freedom of Information Act (FOIA) process. Key requirements for prospective contractors include demonstrated capability in pharmaceutical preparation manufacturing, compliance with FDA standards, and the ability to deliver products in support of CDER research. The solicitation includes an amendment updating the SBCX link for the subcontracting plan, indicating that subcontracting and small business participation may be relevant considerations. The contracting entity is the FDA Office of Acquisition and Grant Services, a federal office within the Food and Drug Administration. The primary point of contact for this opportunity is Nick Sartain, who can be reached at [email protected] or by phone at 301-796-1988. The solicitation is active, with a response deadline of May 15, 2026, at 18:05. Interested contractors should review the attached combined synopsis/solicitation and amendment documents for detailed requirements and submission instructions. This opportunity is well-suited for firms with established expertise in pharmaceutical manufacturing and a track record of supporting government research initiatives. Contractors should ensure alignment with the NAICS classification and be prepared to meet FDA quality and regulatory standards throughout the contract lifecycle. For further information and access to solicitation documents, contractors may visit the official SAM.gov opportunity page at https://sam.gov/opp/c1c1dfb5988b4bd8ad101adfccd93d36/view.